Zydus and Bioeq partner for US biosimilar commercialization

Zydus Lifesciences Limited, through its wholly-owned subsidiary Zydus Lifesciences Global FZE, has partnered with Bioeq AG for the licensing, supply, and commercialization of NUFYMCO®, an interchangeable biosimilar to Lucentis® (Ranibizumab), in the U.S. market. The Biologics License Application for NUFYMCO® was approved by the U.S. Food and Drug Administration on December 18, 2025. This collaboration expands Zydus' U.S. biosimilar business.

Under the agreement, Bioeq is responsible for the development, manufacturing, registration, and supply of the finished product. Zydus will manage the commercialization of NUFYMCO® in the U.S. market. Dr. Sharvil P. Patel, managing director of Zydus Lifesciences Limited, highlighted that this partnership leverages combined expertise to accelerate growth and provide affordable ophthalmology care.

The total addressable market opportunity for biosimilar Ranibizumab in the U.S. is estimated at approximately $210 million, according to IQVIA MAT Sep 2025 data. This strategic move aims to broaden treatment options for patients and improve healthcare accessibility through high-quality, affordable therapies.